I wish I could bring only good news but: ONCT-534 trial discontinued

[Maxone73]

We can't always win! 😐

"In the current study, interim Phase 1 results of ONCT-534 did not show clinically meaningful improvements of disease, including prostate-specific antigen (PSA) levels, in the 20 patients treated in eight dosing cohorts with various doses and schedules of administration of ONCT-534. ONCT-534 was generally well tolerated, with dose limiting toxicity observed in 2 of 3 patients at the highest dose tested, 1200 mg given orally once per day."

[MoonRocket]

History is pretty consistent...we rarely win, unfortunately.

[KocoPr]

That is to bad. I Feel for the warriors and thank them for doing the trial.

I really thought attacking the N terminal domain would stop all translations that involved the androgen receptor.

Do we know why it failed? I am wondering if the CRPC patients already had resistance via progesterone receptors or other non AR pathways. I hope they genetically mapped that prior to this treatment so we might gain some insight as to why it failed.

Here is AI on

ONCT-534 is an investigational drug developed by Oncternal Therapeutics, primarily aimed at treating metastatic castration-resistant prostate cancer (mCRPC). It works as a dual-action androgen receptor inhibitor (DAARI), meaning it targets both the ligand-binding domain (LBD) and the N-terminal domain (NTD) of the androgen receptor (AR). This dual mechanism is particularly significant as it addresses common resistance mechanisms seen in advanced prostate cancer, such as AR splice variants and LBD mutations, which are typically resistant to existing therapies like enzalutamide or abiraterone .

Preclinical studies have shown that ONCT-534 has promising anti-tumor activity in models resistant to other AR-targeted therapies, making it a potential treatment for patients who have relapsed or are refractory to current AR inhibitors . Additionally, the drug has received FDA fast-track designation, which will help expedite its development and review due to the significant unmet need for effective treatments in mCRPC .

Currently, ONCT-534 is being evaluated in a phase 1/2 clinical trial, where its safety, tolerability, and anti-tumor activity are being assessed in patients with advanced prostate cancer .

[Maxone73 in reply to KocoPr]

No, they have not specified what went wrong. But they are saying that with the experience acquired and the platform they have created, they want to try to come up with something different to use as DAARI.

[littleCar]

Disappointed😞! I had my fingers crossed for this one.